{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:54:57Z","timestamp":1794639297642,"version":"4.9.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1097\/01.bor.0000218949.19860.d1","type":"journal-article","created":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T05:15:26Z","timestamp":1143695726000},"page":"277-281","source":"Crossref","is-referenced-by-count":154,"title":["Interleukin-6 in rheumatoid arthritis"],"prefix":"10.1097","volume":"18","author":[{"given":"Norihiro","family":"Nishimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","article-title":"Rheumatoid arthritis: pathophysiology and implications for therapy","volume":"322","author":"Harris","year":"1990","journal-title":"N Engl J Med"},{"key":"R2-11-20210128","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/art.1780311003","article-title":"Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis","volume":"31","author":"Cush","year":"1988","journal-title":"Arthritis Rheum"},{"key":"R3-11-20210128","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1196\/annals.1361.123","article-title":"Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?","volume":"1051","author":"Voll","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60532-5","article-title":"Interleukin-6 in biology and medicine","volume":"54","author":"Akira","year":"1993","journal-title":"Adv Immunol"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/eji.1830181122","article-title":"Excessive production of interleukin 6\/B cell stimulatory factor-2 in rheumatoid arthritis","volume":"18","author":"Hirano","year":"1988","journal-title":"Eur J Immunol"},{"key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.1780310614","article-title":"Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis","volume":"31","author":"Houssiau","year":"1988","journal-title":"Arthritis Rheum"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00307733","article-title":"Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis","volume":"13","author":"Sack","year":"1993","journal-title":"Rheumatol Int"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/ard.52.3.232","article-title":"Serum interleukin 6 levels in rheumatoid arthritis: correlation with clinical and laboratory indices of disease activity","volume":"52","author":"Madhok","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"R13-11-20210128","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1182\/blood.V84.5.1434.1434","article-title":"Effects of recombinant human interleukin-6 in cancer patients: a phase I\u2013II study","volume":"84","author":"van Gameren","year":"1994","journal-title":"Blood"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0014-5793(88)80766-X","article-title":"Recombinant human interleukin-6(IL-6\/BSF-2\/HSF) regulates the synthesis of acute phase proteins in human hepatocytes","volume":"232","author":"Castell","year":"1988","journal-title":"FEBS Lett"},{"key":"R16-11-20210128","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood.V74.4.1241.1241","article-title":"Interleukin-6 is a potent thrombopoietic factor in vivo in mice","volume":"74","author":"Ishibashi","year":"1989","journal-title":"Blood"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.11143","article-title":"Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis","volume":"48","author":"Nakahara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1073\/pnas.90.24.11924","article-title":"Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6","volume":"90","author":"Tamura","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/03009740510026373","article-title":"IL-6 promoter polymorphism in patients with rheumatoid arthritis","volume":"34","author":"Pawlik","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"R20-11-20210128","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.187.4.461","article-title":"Interleukin-6 is required for the development of collagen-induced arthritis","volume":"187","author":"Alonzi","year":"1998","journal-title":"J Exp Med"},{"key":"R21-11-20210128","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/1529-0131(199908)42:8<1635::AID-ANR11>3.0.CO;2-Q","article-title":"Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice","volume":"42","author":"Sasai","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1172\/JCI200421795","article-title":"Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice","volume":"114","author":"Hata","year":"2004","journal-title":"J Clin Invest"},{"key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1084\/jem.20020619","article-title":"A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis","volume":"196","author":"Atsumi","year":"2002","journal-title":"J Exp Med"},{"key":"R24-11-20210128","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1529-0131(199812)41:12<2117::AID-ART6>3.0.CO;2-P","article-title":"Blockage of Interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis","volume":"41","author":"Takagi","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1006\/clim.2000.4989","article-title":"Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys","volume":"98","author":"Mihara","year":"2001","journal-title":"Clin Immunol"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin-6 receptor monoclonal antibody","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R27-11-20210128","first-page":"1426","article-title":"Toxicity, pharmacokinetics, and dose finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody, MRA, in rheumatoid arthritis: phase I\/II clinical study","volume":"30","author":"Nishimoto","year":"2003","journal-title":"J Rheumatol"},{"key":"R28-11-20210128","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"suppl","key":"R29-11-20210128","first-page":"S652","article-title":"Efficacy of IL-6 receptor antagonist MRA in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA) [abstract]","volume":"48","author":"Maini","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R30-11-20210128","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/art.20944","article-title":"Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis","volume":"52","author":"Yokota","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R31-11-20210128","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","article-title":"A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease","volume":"126","author":"Ito","year":"2004","journal-title":"Gastroenterology"},{"key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman's disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.bor.0000218949.19860.d1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:23:07Z","timestamp":1785856987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200605000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.bor.0000218949.19860.d1","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}